NovaBridge Biosciences (NBP) Current Assets (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Current Assets for 8 consecutive years, with $217.5 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets rose 23.11% year-over-year to $217.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $217.5 million (up 23.11% YoY) and the FY2025 annual result came in at $217.5 million, up 23.11% from the prior year.
• Current Assets eased to $217.5 million in Q4 2025 per NBP's latest filing, from $232.8 million in the prior quarter.
• Over the last five years, Current Assets for NBP reached as high as $747.9 billion in Q4 2021 and fell as low as $167.6 million in Q2 2025.
• A 5-year average of $57.8 billion and a median of $232.8 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets jumped 92655.2% — and 2022, when it sank 99.93%.
• Year by year, Current Assets stood at $747.9 billion in 2021, then plunged by 99.93% to $509.9 million in 2022, then plunged by 36.35% to $324.5 million in 2023, then slumped by 45.55% to $176.7 million in 2024, then increased by 23.11% to $217.5 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $217.5 million, $232.8 million, and $167.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.